Copanlisib is an imidazoquinazoline derivative substituted with a (2-aminopyrimidine-5-carbonyl)amino group at position 5, a methoxy group at position 7, and a 3-(morpholin-4-yl)propoxy group at position 8. It is an intravenous pan-class I phosphatidylinositol 3-kinase (EC 2.7.1.137) inhibitor used to treat relapsed follicular lymphoma in patients who have received at least two prior systemic therapies. It functions as an antineoplastic agent and apoptosis inducer, and belongs to the classes of morpholines, aromatic ethers, diethers, tertiary amino compounds, secondary carboxamides, pyrimidinecarboxamides, aminopyrimidines, and imidazoquinazolines.
